KSI 101
Alternative Names: KSI-101; KSI-501PLatest Information Update: 25 Nov 2024
Price :
$50 *
At a glance
- Originator Kodiak Sciences
- Class Anti-inflammatories; Eye disorder therapies; Immunoglobulin Fc fragments; Recombinant fusion proteins
- Mechanism of Action Interleukin 6 inhibitors; Vascular endothelial growth factors inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Retinal oedema
Most Recent Events
- 14 Nov 2024 Kodiak Sciences plans phase-IIb/III PEAK and PINNACLE trials for Retinal oedema (Intravitreal) in 2024 (Kodiak Sciences pipeline; March 2024)
- 14 Aug 2024 Kodiak Sciences initiates enrollment in the phase Ib APEX trial in Retinal oedema (Intravitreous)
- 30 Jun 2024 Kodiak Sciences submits IND application for KSI 101 in in Retinal oedema